Aleksandr Petrov

发表

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, N. Thornberry, R. S. Roy, 2005, Journal of medicinal chemistry.

Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors.

Joseph L Duffy, Aleksandr Petrov, N. Thornberry, 2005, Bioorganic & medicinal chemistry letters.

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors.

Ping Chen, N. Thornberry, B. Leiting, 2004, Bioorganic & medicinal chemistry letters.

4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors.

Aleksandr Petrov, N. Thornberry, B. Leiting, 2004, Bioorganic & medicinal chemistry letters.

Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.

Aleksandr Petrov, N. Thornberry, B. Leiting, 2006, Bioorganic & medicinal chemistry letters.

(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, N. Thornberry, R. S. Roy, 2006, Journal of medicinal chemistry.

A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.

A. Pocai, A. Pessi, Alessia Santoprete, 2013, Bioorganic & medicinal chemistry.

Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus.

M. Erion, D. Kelley, Dan Zhou, 2016, American journal of physiology. Endocrinology and metabolism.

An automated electrophysiology serum shift assay for K(V) channels.

O. McManus, J. Herrington, G. Eiermann, 2008, Assay and drug development technologies.

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Michael E. Lassman, N. Thornberry, Gaochao Zhou, 2009, Diabetes.

GPR120 suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy[S]

Margaret S. Wu, M. Erion, Vinit Shah, 2017, Journal of Lipid Research.

Quantifying ceramide kinetics in vivo using stable isotope tracers and LC-MS/MS.

Guo-Fang Zhang, D. Kelley, D. McLaren, 2018, American journal of physiology. Endocrinology and metabolism.

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

Yun-ping Zhou, J. Berger, N. Thornberry, 2008, Diabetes.

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.

N. Thornberry, B. Leiting, G. Eiermann, 2007, Bioorganic & medicinal chemistry letters.

INNOVATIVE METHODOLOGY Quantifying ceramide kinetics in vivo using stable isotope tracers and LC-MS/MS

Guo-Fang Zhang, D. Kelley, D. McLaren, 2018 .

Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.

A. Pocai, Jennifer R. Kosinski, G. Eiermann, 2012, American journal of physiology. Endocrinology and metabolism.

Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists.

Yun-ping Zhou, J. Berger, N. Thornberry, 2010, Bioorganic & medicinal chemistry letters.

The Role of Voltage-Gated Potassium Channels Kv2.1 and Kv2.2 in the Regulation of Insulin and Somatostatin Release from Pancreatic Islets

M. Jensen, C. Newgard, Yun-ping Zhou, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin.

Youwei Yan, Ping Chen, J. Metzger, 2015, Bioorganic & medicinal chemistry letters.

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors.

Ping Chen, N. Thornberry, B. Leiting, 2004, Bioorganic & medicinal chemistry letters.

GLP-1/GCGR dual agonism reverses obesity in mice Short-running title: Dual GLP-1/GCGR agonist for the treatment of obesity

Michael E. Lassman, N. Thornberry, Gaochao Zhou, 2009 .

Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors.

G. Scapin, N. Thornberry, B. Leiting, 2007, Bioorganic & medicinal chemistry letters.

Targeting a ceramide double bond improves insulin resistance and hepatic steatosis

James E. Cox, Mark D. Erion, Jared Rutter, 2019, Science.

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

A. Woods, D. Zaller, N. Thornberry, 2005, Diabetes.

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

Kathy Lyons, Ping Chen, Dennis Feng, 2014, Journal of medicinal chemistry.

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy

M. Erion, D. Kemp, S. Prahalada, 2017, Science.

Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia[S]

N. Geoghagen, L. Mitnaul, Peggy H. Wong, 2012, Journal of Lipid Research.

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.

Yun-ping Zhou, N. Thornberry, J. Mu, 2009, European journal of pharmacology.

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.

G. Scapin, N. Thornberry, R. S. Roy, 2008, Journal of medicinal chemistry.

GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia

Margaret S. Wu, M. Erion, R. Sherwin, 2018, Diabetes.

The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.

J. Metzger, G. Scapin, S. Xu, 2016, Bioorganic & medicinal chemistry letters.

Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.

G. Scapin, N. Thornberry, B. Leiting, 2006, Bioorganic & medicinal chemistry letters.

Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors.

G. Scapin, N. Thornberry, R. S. Roy, 2009, Bioorganic & medicinal chemistry letters.

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia[S]

N. Geoghagen, L. Mitnaul, Peggy H. Wong, 2012, Journal of Lipid Research.

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.

G. Scapin, N. Thornberry, R. S. Roy, 2008, Journal of medicinal chemistry.